Although the findings in this study do not fully determine other downstream signaling targets such as IRS, concentration-response curves, and time-course studies for both NECA and insulin, they clearly support the possibility of employing adenosine analogues to develop new treatments for a wide range of metabolic conditions, such as diabetes and obesity. The gene discussed is IARS1; the disease is obesity due to melanocortin 4 receptor deficiency.